BPC-157 does not cause skin thinning
10.1210/en.2003-1359 Endocrinology 46 LarssonC
65,66 Of all adverse events reported, psychiatric side-effects of GLP-1 RAs are not frequent and account for 1.24.4% of events
doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Otros estudios sugieren que su eficacia es mayor en personas con niveles bajos de carnitina, como ancianos, veganos, o individuos con enfermedades metablicas